ADDISON artificial ielligence has been launched as a powerful model that will help in the discovery of new pharmaceutical compounds and processes to treat diseases.
American and Canadian life sciences company under the manageme of Merck KGaA of Germany, a leading science and technology company, has launched AIDDISON drug developme software. This system combines generative artificial ielligence tools, machine learning and drug design with the aim of accelerating the developme of new drugs.
AIDDISON software has been trained with data from more than 20 years of research by scieists and can ideify more than 60 billion compounds that can poteially be used in medicines. These compounds, which have characteristics such as non-toxicity, solubility, and stability in the body, after being ideified, are checked by the software to define the way to produce the most efficie compound for obtaining medicine.
Karen Madden, Chief Technology Officer of Merck KGaA's life sciences business, believes: “Given the number of paties waiting for drugs, it will take 10 years to bring a new drug combination to the market and it will cost more than 2 billion dollars; While the ADDISON platform is able to be used in any laboratory to ideify the most suitable combination to create a new drug.
Discovering a new drug compound is a long process; Moreover, the chance of success of an initial candidate is only 10%. These facts remind us that the developme of a new drug requires a lot of financial resources and expert staff in addition to time. In this situation, models like AIDDISON can ideify efficie leads from among many drug candidates and in this way, in addition to saving time and resources, they can also increase the chance of success of the ideified compounds. It is predicted that artificial ielligence can save more than 70 billion dollars in the process and up to 70% in the time and costs of drug discovery by 2028.
